Bremer Bank National Association reduced its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.6% in the second quarter, Holdings Channel.com reports. The firm owned 18,523 shares of the company’s stock after selling 692 shares during the quarter. Bremer Bank National Association’s holdings in Johnson & Johnson were worth $3,288,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Family CFO Inc purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $26,000. RE Dickinson Investment Advisors LLC boosted its holdings in Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after acquiring an additional 98 shares during the period. Advanced Research Investment Solutions LLC boosted its holdings in Johnson & Johnson by 200.0% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after acquiring an additional 120 shares during the period. Professional Financial Advisors LLC boosted its holdings in Johnson & Johnson by 47.9% during the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after acquiring an additional 68 shares during the period. Finally, Joseph P. Lucia & Associates LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at about $38,000. 68.59% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
Johnson & Johnson stock opened at $167.60 on Monday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $440.65 billion, a P/E ratio of 24.40, a PEG ratio of 2.99 and a beta of 0.61. The stock’s 50 day moving average is $168.96 and its 200 day moving average is $174.29. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.
Johnson & Johnson announced that its Board of Directors has approved a stock repurchase plan on Wednesday, September 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.70%. Johnson & Johnson’s payout ratio is currently 65.79%.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on JNJ shares. UBS Group lowered their price target on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Morgan Stanley lowered their price target on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a research report on Monday, September 12th. Wells Fargo & Company upped their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. SVB Leerink lowered their price target on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Finally, Citigroup lowered their price target on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.78.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.